Glucose transporter-1 as a new therapeutic target in laryngeal carcinoma

Journal of International Medical Research

Volumn 38, Issue 6, 2010, Pages 1885-1892

  Luo, X M ^a   Zhou, S H ^a   Fan, J ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Glucose transporter 1 (glut 1); Laryngeal carcinoma; Targeted treatment

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTISENSE OLIGODEOXYNUCLEOTIDE; APIGENIN; CISPLATIN; DEOXYGLUCOSE; DOXORUBICIN; GLUCOSE DERIVATIVE; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; DRUG EFFICACY; ENZYME INHIBITION; GLIOMA; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HYPOXEMIA; LARYNX CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RNA INTERFERENCE; TREATMENT INDICATION; UPREGULATION;

EID: 78650836005     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800601     Document Type: Article

References (82)

1. Warburg O: On the origin of cancer cells. Science 1956; 123: 309-314.
2. Nijsten MW, van Dam GM: Hypothesis: using the Warburg effect against cancer by reducing glucose and providing lactate. Med Hypotheses 2009; 73: 48-51.
3. Wahl H, Daudi S, Kshirsagar M, et al: Expression of metabolically targeted biomarkers in endometrial carcinoma. Gynecol Oncol 2010; 116: 21-27.
4. Robey IF, Stephen RM, Brown KS, et al: Regulation of the Warburg effect in early- passage breast cancer cells. Neoplasia 2008; 10: 745-756.
5. Busk M, Horsman MR, Kristjansen PE, et al: Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer 2008; 122: 2726-2734.
6. Gillies RJ, Gatenby RA: Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? J Bioenerg Biomembr 2007; 39: 251-257.
7. Li LF, Zhou SH, Zhao K, et al: Clinical significance of FDG single-photon emission computed tomography: computed tomography in the diagnosis of head and neck cancers and study of its mechanism. Cancer Biother Radiopharm 2008; 23: 701-714.
8. Tian M, Zhang H, Nakasone Y, et al: Expression of Glut-1 and Glut-3 in untreated oral squamous cellcarcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging 2004; 31: 5-12.
9. de Geus-Oei LF, van Krieken JH, Aliredjo RP, et al:Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 2007; 55: 79-87.
10. Kurokawa T, Yoshida Y, Kawahara K, et al: Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 2004; 109: 926-932.
11. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med 2004; 45: 22-29.
12. 18F-fluorodeoxyglucose positron emission tomography. Nucl Med Commun 2009; 30: 594-601.
13. 18F-FDG PET in hepatocellular carcinoma. Int J Oncol 2008; 33: 1047-1054.
14. Higashi T, Tamaki N, Honda T, et al: Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 1997; 38: 1337-1344.
15. Brown RS, Leung JY, Fisher SJ, et al: Intratumoral distribution of tritiated-FDG in breast carcinoma: 1890 correlation between Glut-1 expression and FDG uptake. J Nucl Med 1996; 37: 1042-1047.
16. Wood IS, Trayhurn P: Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 2003; 89: 3-9.
17. Rivenzon-Segal D, Rushkin E, Polak-Charcon S, et al: Glucose transporters and transport kinetics in retinoic acid-differentiated T47D human breast cancer cells. Am J Physiol Endocrinol Metab 2000; 279: E508-E519.
18. Amann T, Hellerbrand C: GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets 2009; 13: 1411-1427.
19. Pessin JE, Bell GI: Mammalian facilitative glucose transporter family: structure and molecular regulation. Annu Rev Physiol 1992; 54: 911-930.
20. Stokkel MP, Linthorst MF, Borm JJ, et al: A reassessment of bone scintigraphy and commonly tested pretreatment biochemical parameters in newly diagnosed osteosarcoma. J Cancer Res Clin Oncol 2002; 128: 393-399.
21. Noguchi Y, Saito A, Miyagi Y, et al: Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Lett 2000; 154: 175-182.
22. Kawamura T, Kusakabe T, Sugino T, et al: Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 2001; 92: 634-641.
23. 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 2002; 43: 173-180.
24. 18F]FDG uptake in non-small cell lung cancer Eur J Nucl Med 2000; 27: 1778-1785.
25. Amann T, Maegdefrau U, Hartmann A, et al: GLUT1 expression is increased in hepato cellular carcinoma and promotes tumori genesis. Am J Pathol 2009; 174: 1544-1552.
26. Demasi AP, Costa AF, Altemani A, et al: Glucose transporter protein 1 expression in mucoepidermoid carcinoma of salivary gland: correlation with grade of malignancy. Int J Exp Pathol 2010; 91: 107-113.
27. McGuire BB, Fitzpatrick JM: Biomarkers in renal cell carcinoma. Curr Opin Urol 2009; 19: 441-446.
28. Parente P, Coli A, Massi G, et al: Immuno- histochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions. J Exp Clin Cancer Res 2008; 27: 34.
29. Ahrens WA, Ridenour RV 3rd, Caron BL, et al: GLUT-1 expression in mesenchymal tumors: an immunohistochemical study of 247 soft tissue and bone neoplasms. Hum Pathol 2008; 39: 1519-1526.
30. Endo M, Tateishi U, Seki K, et al: Prognostic implications of glucose transporter protein-1 (Glut-1) overexpression in bone and soft-tissue sarcomas. Jpn J Clin Oncol 2007; 37: 955-960.
31. Eckert AW, Lautner MH, Taubert H, et al: Expression of Glut-1 is a prognostic marker for oral squamous cell carcinoma patients. Oncol Rep 2008; 20: 1381-1385.
32. Legan M, Luzar B, Marolt VF: Expression of cyclooxygenase-2, glucose transporter-1 and angiogenesis in gallbladder carcinomas and their impact on prognosis. Scand J Gastroenterol 2009; 44: 1101-1108.
33. Zhou S, Wang S, Wu Q, et al: Expression of glucose transporter-1 and -3 in the head and neck carcinoma-the correlation of the expression with the biological behaviors. ORL J Otorhinolaryngol Relat Spec 2008; 70: 189-194.
34. Farhadieh RD, Rees CG, Yang JL, et al: Radiotherapy in larynx squamous cell carcinoma is not associated with an increased diagnosis of second primary tumours. Clin Oncol (R Coll Radiol) 2009; 21: 315-319.
35. Schrijvers ML, van der Laan BF, de Bock GH, et al: Overexpression of intrinsic hypoxia markers HIF1α and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 2008; 72: 161-169.
36. Cikojević D, Glunić I, Klancnik M: Cigarette smoking and progression of laryngeal lesions. Coll Antropol 2010; 34(suppl 1): 45-48.
37. Tai P, Yu E, Shiels R, et al: Long-term survival rates of laryngeal cancer patients treated by radiation and surgery, radiation alone, and surgery alone: studied by lognormal and Kaplan-Meier survival methods. BMC Cancer 2005; 5: 13.
38. Ghaffar S, Ikram M, Imam SZ, et al: Comparison of different treatment modalities in advanced laryngeal hypopharyngeal squamous cell carcinoma. J Coll Physicians Surg Pak 2010; 20: 171-174.
39. Varghese BT, Sebastian P, Mathew A: Treatment outcome in patients undergoing surgery for carcinoma larynx and hypopharynx: a follow-up study. Acta Otolaryngol 2009; 129: 1480-1485.
40. Bajaj Y, Shayah A, Sethi N, et al: Clinical outcomes of total laryngectomy for laryngeal carcinoma. Kathmandu Univ Med J (KUMJ) 2009; 7: 258-262.
41. 1a glottic carcinoma? Eur Arch Otorhinolaryngol 2010; 267: 743-750.
42. Tuna B, Katilmiş H, Oztürkcan S, et al: Outcome of conservation surgery for laryngeal carcinoma: an 8-year trial. Eur Arch Otorhinolaryngol 2009; 266: 1681-1686.
43. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
44. Johansen LV, Grau C, Overgaard J: Supraglottic carcinoma: patterns of failure and salvage treatment after curatively intended radiotherapy in 410 consecutive patients. Int J Radiat Oncol Biol Phys 2002; 53: 948-958.
45. Nix P, Cawkwell L, Patmore H, et al: Bcl-2 expression predicts radiotherapy failure in laryngeal cancer. Br J Cancer 2005; 92: 2185-2189.
46. Louw L, Claassen J: Rationale for adjuvant fatty acid therapy to prevent radiotherapy failure and tumor recurrence during early laryngeal squamous cell carcinoma. Prostaglandins Leukot Essent Fatty Acids 2008; 78: 21-26.
47. Xu RH, Pelicano H, Zhou Y, et al: Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005; 65: 613-621.
48. Zhou SH, Fan J, Chen XM, et al: Inhibition of cell proliferation and glucose uptake in human laryngeal carcinoma cells by antisense oligonucleotides against glucose transporter-1. Head Neck 2009; 31: 1624-1633.
49. De Schutter H, Landuyt W, Verbeken E, et al: The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy. BMC Cancer 2005; 5: 42.
50. Chan JY, Chu AC, Fung KP: Inhibition of P- glycoprotein expression and reversal of drug resistance of human hepatoma HepG2 cells by multidrug resistance gene (mdr1) antisense RNA. Life Sci 2000; 67: 2117-2124.
51. Chen CP, Li XX, Zhang LR, et al: Synthesis of antisense oligonucleotide-peptide conjugate targeting to GLUT-1 in HepG-2 and MCF-7 cells. Bioconjug Chem 2002; 13: 525-529.
52. Ito S, Fukusato T, Nemoto T, et al: Coexpression of glucose transporter 1 and matrix metallo-proteinase-2 in human cancers. J Natl Cancer Inst 2002; 94: 1080-1091.
53. Chan JY, Kong SK, Choy YM, et al: Inhibition of glucose transporter gene expression by antisense nucleic acids in HL-60 leukemia cells. Life Sci 1999; 65: 63-70.
54. Choi JW, Yoon DJ, Lee HW, et al: Antisense GLUT1 RNA suppresses the transforming phenotypes of NIH 3T3 cells transformed by N- Ras. Yonsei Med J 1995; 36: 480-486.
55. Samih N, Hovsepian S, Aouani A, et al: Glut-1 translocation in FRTL-5 thyroid cells: role of phosphatidylinositol 3-kinase and N-glyco-sylation. Endocrinology 2000; 141: 4146-4155.
56. Melstrom LG, Salabat MR, Ding XZ, et al: Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas 2008; 37: 426-431.
57. Granville CA, Memmott RM, Gills JJ, et al: Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2006; 12: 679-689.
58. Wang W, Xu GL, Jia WD, et al: Expression and correlation of hypoxia-inducible factor-1α, vascular endothelial growth factor and microvessel density in experimental rat hepatocarcinogenesis. J Int Med Res 2009; 37: 417-425.
59. McCarty MF, Barroso-Aranda J, Contreras F: Practical strategies for suppressing hypoxia- inducible factor activity in cancer therapy. Med Hypotheses 2010; 74: 789-797.
60. Seeber LM, Zweemer RP, Verheijen RH, et al: Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management. Obstet Gynecol Int 2010; 2010: 580971.
61. Seagroves TN, Ryan HE, Lu H, et al: Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol Cell Biol 2001; 21: 3436-3444.
62. Ogane N, Yasuda M, Shimizu M, et al: Clinicopathological implications of expressions of hypoxia-related molecules in esophageal superficial squamous cell carcinoma. Ann Diagn Pathol 2010; 14: 23-29.
63. Evans A, Bates V, Troy H, et al: Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother Pharmacol 2008; 61: 377-393.
64. Kamlah F, Eul BG, Li S, et al: Intravenous injection of siRNA directed against hypoxia- inducible factors prolongs survival in a Lewis lung carcinoma cancer model. Cancer Gene Ther 2009; 16: 195-205.
65. Kaplan O, Navon G, Lyon RC, et al: Effects of 2-deoxyglucose on drug-sensitive and drug- resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism. Cancer Res 1990; 50: 544-551.
66. Aft RL, Zhang FW, Gius D: Evaluation of 2-deoxy- D-glucose as a chemotherapeutic agent: mechanism of cell death. Br J Cancer 2002; 87: 805-812.
67. Maschek G, Savaraj N, Priebe W, et al: 2-Deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non- small cell lung cancers in vivo. Cancer Res 2004; 64: 31-34.
68. Maher JC, Savaraj N, Priebe W, et al: Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression. Pancreas 2005; 30: e34-e39.
69. Simons AL, Ahmad IM, Mattson DM, et al: 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res 2007; 67: 3364-3370.
70. Prasanna VK, Venkataramana NK, Dwarakanath BS, et al: Differential responses of tumors and normal brain to the combined treatment of 2-DG and radiation in glioablastoma. J Cancer Res Ther 2009; 5(suppl 1): S44-S47.
71. Gupta S, Farooque A, Adhikari JS, et al: Enhancement of radiation and chemo- therapeutic drug responses by 2-deoxy-D-glucose in animal tumors. J Cancer Res Ther 2009; 5(suppl 1): S16-S20.
72. Dwarakanath BS, Singh D, Banerji AK, et al: Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. J Cancer Res Ther 2009; 5(suppl 1): S21-S26.
73. Furuta E, Okuda H, Kobayashi A, et al: Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta 2010; 1805: 141-152.
74. Jason TL, Berg RW, Vincent MD, et al: Antisense targeting of thymidylate synthase (TS) mRNA increases TS gene transcription and TS protein: effects on human tumor cell sensitivity to TS enzyme-inhibiting drugs. Gene Expr 2007; 13: 227-239.
75. Hunter AM, LaCasse EC, Korneluk RG: The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007; 12: 1543-1568.
76. Tschaharganeh D, Ehemann V, Nussbaum T, et al: Non-specific effects of siRNAs on tumor cells with implications on therapeutic applicability using RNA interference. Pathol Oncol Res 2007; 13: 84-90.
77. Castanotto D, Rossi JJ: The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009; 457: 426-433.
78. DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al: A randomized, double-blind, placebo- controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA 2010; 107: 8800-8805.
79. Shen J, Samul R, Silva RL, et al: Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006; 13: 225-234.
80. Fire A, Xu S, Montgomery MK, et al: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811.
81. Ramanathan A, Wang C, Schreiber SL: Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci U S A 2005; 102: 5992-5997.
82. Macheda ML, Rogers S, Best JD: Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005; 202: 654-662.